Endocrinology System
Endocrinology
High-yield endocrinology for USMLE Step 2/3 — thyroid disorders, adrenal/pituitary pathology, diabetes pharmacology, calcium/bone disease, and the framework for understanding all endocrine testing.
By Dr. Marish Asudani · Published · Updated
Which Divine Intervention endocrinology episodes should I study for Step 2?
This guide pulls together 13 Divine Intervention endocrinology episodes plus 4 Rapid Review episodes for Step 2/3, grouped into 4 clusters: Thyroid, Adrenal & Pituitary, Diabetes & Glucose, and Calcium & Bone. Each episode has high-yield bullet notes and a Listen link, covering thyroid nodule workup, Cushing's and dexamethasone testing, insulin types and DKA management and hypercalcemia. One rule to know cold: in MEN2A/2B, screen for and treat pheochromocytoma before thyroidectomy.
Thyroid
The thyroid cluster covers the complete spectrum from benign nodule workup through thyroid cancer staging, and the acute management of thyroid storm — a condition where getting the order of drug administration wrong can be lethal. RR 89 and RR 97 bring in the pharmacology of Graves disease and the newest USMLE angles on thyroid storm management.
EP376
The Clutch Thyroid Cancer Podcast
- Thyroid nodule workup: TSH first — if low → hot nodule (functioning) → radioactive iodine scan (scintigraphy); if normal/high → cold nodule → ultrasound → FNA (fine needle aspiration) if ≥1cm solid or suspicious features
- Hot nodule: Rarely malignant — autonomous functioning adenoma. Cold nodule: higher malignancy risk → FNA
- Papillary thyroid cancer: Most common (80%). Psammoma bodies, Orphan Annie nuclei, nuclear grooves. Spread: lymph nodes. Best prognosis. RET/PTC rearrangement
- Follicular: Spread hematogenously (bone, lung). Capsular/vascular invasion distinguishes from adenoma. No psammoma bodies
- Medullary: C-cells → calcitonin. Associated with MEN2A (RET mutation + pheo + parathyroid) and MEN2B (RET + pheo + mucosal neuromas + marfanoid). Screen family members for RET mutations
- Anaplastic: Worst prognosis — rapidly fatal. Large neck mass compressing trachea. Old patient. Mostly palliative
Thyroid Cancer Master Table
| Type | Frequency | Origin | Spread | Marker | Prognosis |
|---|---|---|---|---|---|
| Papillary | 80% | Follicular cells | Lymph nodes (not hematogenous) | Thyroglobulin | Excellent — 10-yr survival >90% |
| Follicular | 10% | Follicular cells | Hematogenous (bone, lung) | Thyroglobulin | Good — must invade capsule to diagnose |
| Medullary | 5% | Parafollicular C-cells | Local + hematogenous | Calcitonin + CEA | Moderate — RET mutation (MEN2A/2B) |
| Anaplastic | <1% | Follicular cells (dediff.) | Rapidly local + distant | None specific | Very poor — months |
Thyroid Nodule Algorithm
Step 1: Check TSH.
TSH low → Hot nodule → Radioactive iodine uptake scan → Hot = benign autonomous adenoma, don't FNA.
TSH normal/high → Cold nodule → Ultrasound → If ≥1cm or suspicious → FNA.
FNA result: Indeterminate → repeat; malignant → surgery; benign → follow up.
MEN Syndromes
| Syndrome | Components | Gene |
|---|---|---|
| MEN1 | Parathyroid (hyperCa) + Pituitary adenoma + Pancreatic endocrine tumors (Zollinger-Ellison, insulinoma, VIPoma, glucagonoma) | MEN1 (menin, chr 11) |
| MEN2A | Medullary thyroid cancer + Pheochromocytoma + Parathyroid hyperplasia | RET proto-oncogene |
| MEN2B | Medullary thyroid cancer + Pheochromocytoma + Mucosal neuromas + Marfanoid habitus (NO parathyroid) | RET proto-oncogene |
Pheo Before Surgery — Always
In MEN2A/2B: ALWAYS screen for and treat pheochromocytoma BEFORE thyroidectomy. Operating on a patient with undiagnosed pheo = hypertensive crisis on the table. Order: pheo workup first, then parathyroid, then thyroid surgery.
RR 89EP431
Graves Disease, Hyperthyroidism & AFib
- Hyperthyroidism diagnosis: TSH low, T3/T4 high, thyroglobulin high (like C-peptide of thyroid — elevated when gland is actively secreting, NOT elevated in exogenous thyroid hormone ingestion)
- AFib + hyperthyroidism: Thyroid hormone ↑ β1 receptors on cardiac myocytes → ↑ heart rate + irregular QRS (narrow) = AFib. Most common arrhythmia in hyperthyroidism
- Graves disease: TSH receptor stimulating antibodies (TRAb/TSI) → continuous stimulation. Exophthalmos (fibroblasts express TSH receptors → glycosaminoglycan accumulation). Pretibial myxedema
- Graves treatment: Methimazole (1st line, except 1st trimester pregnancy → use PTU); β-blocker for symptom control; radioactive iodine (131I) if definitive therapy desired
- Thyroid storm: Life-threatening hyperthyroidism. Order matters: (1) PTU blocks synthesis + conversion T4→T3; (2) Lugol's iodine blocks release (give AFTER PTU — Wolff-Chaikoff); (3) β-blocker (propranolol); (4) steroids (hydrocortisone) — block T4→T3 conversion
Thyroid Storm — Order of Treatment
| Step | Drug | Mechanism | Why This Order |
|---|---|---|---|
| 1 | PTU (or methimazole) | Blocks thyroid peroxidase → no new hormone synthesis; PTU also blocks T4→T3 peripheral conversion | Must block synthesis first before blocking release |
| 2 | Lugol's iodine (potassium iodide) | Wolff-Chaikoff effect: high iodine transiently suppresses thyroid hormone release | Give AFTER PTU — giving iodine first provides substrate for MORE hormone synthesis |
| 3 | Propranolol (β-blocker) | Controls sympathetic symptoms (tachycardia, tremor, anxiety); also blocks T4→T3 conversion | Symptomatic control while hormone levels fall |
| 4 | Hydrocortisone (steroids) | Blocks T4→T3 peripheral conversion; treats possible relative adrenal insufficiency | Additive anti-conversion effect; life-saving if adrenal crisis co-exists |
Wolff-Chaikoff Trap
If you give iodine (Lugol's solution) BEFORE PTU, the excess iodine initially provides MORE substrate for thyroid hormone synthesis before the Wolff-Chaikoff suppression effect kicks in → can worsen thyroid storm. Always block synthesis first (PTU/methimazole), then block release (iodine).
Thyroglobulin as Diagnostic Tool
Elevated thyroglobulin: Gland actively secreting → confirms endogenous hyperthyroidism (Graves, toxic nodule, thyroiditis).
Low/undetectable thyroglobulin + hyperthyroidism: Exogenous thyroid hormone ingestion (factitious thyrotoxicosis) — the gland is suppressed, not secreting.
Post-thyroidectomy: Rising thyroglobulin = thyroid cancer recurrence (used as tumor marker).
RR 97EP466
Thyroid Storm Pharmacology — PTU, Propranolol, Lugol
- PTU in 1st trimester: Methimazole is teratogenic (aplasia cutis) in 1st trimester → use PTU instead. Switch to methimazole in 2nd/3rd trimester (PTU hepatotoxic long-term)
- Propranolol blocks T4→T3 conversion peripherally — important in thyroid storm (additive to PTU effect)
- Radioactive iodine (131I): Destroys thyroid tissue. CI in pregnancy. Worsens Graves ophthalmopathy. Patient must be euthyroid first (or use methimazole to stabilize, then stop before 131I)
- Hypothyroidism treatment: Levothyroxine (T4) — take on empty stomach in AM. Monitor TSH 6–8 weeks after dose change. Drugs that reduce absorption: calcium, iron, PPIs, cholestyramine
- Myxedema coma: Severe hypothyroidism emergency — hypothermia, AMS, bradycardia, hyponatremia. Treat: IV levothyroxine + IV hydrocortisone (rule out adrenal insufficiency first)
Hypothyroidism vs Hyperthyroidism — TSH Rules
| Condition | TSH | Free T4 | Cause |
|---|---|---|---|
| Primary hypothyroidism | ↑↑ | ↓ | Hashimoto's (anti-TPO, anti-thyroglobulin Ab); most common in US |
| Secondary hypothyroidism | ↓ or normal | ↓ | Pituitary failure (Sheehan's, pituitary adenoma) |
| Primary hyperthyroidism (Graves) | ↓↓ | ↑↑ | TRAb (stimulating), diffuse goiter, eye disease |
| Toxic multinodular goiter | ↓ | ↑ | Multiple autonomous nodules; no eye disease |
| Thyroiditis (subacute) | ↓ (early) | ↑ (early) | de Quervain's — painful; post-viral; tender thyroid |
| Exogenous thyroid | ↓↓ | ↑ | Factitious — thyroglobulin LOW (not secreting) |
Subacute (de Quervain's) Thyroiditis Phases
Phase 1 (weeks): Gland inflamed → stored T4/T3 releases → hyperthyroid symptoms, painful thyroid, ↓ TSH, ↓ RAI uptake.
Phase 2: Gland depleted → hypothyroid symptoms.
Phase 3: Recovery → euthyroid. Treat phase 1 with NSAIDs (or steroids if severe); β-blocker for symptoms.
Adrenal, Pituitary & Endocrine Testing
The adrenal/pituitary cluster is anchored by EP440's deep dive into the high-dose dexamethasone suppression test — a test that catches more exam-takers off guard than almost any other. The endocrine testing framework episodes (EP514 and EP602) provide the universal logic that makes every stimulation and suppression test interpretable without memorization.
EP440
High-Dose Dexamethasone — New USMLE Perspective
- Cushing's diagnosis algorithm: Screen with 24-hr urine cortisol OR late-night salivary cortisol OR low-dose dexamethasone suppression test → if positive (cortisol not suppressed) → check ACTH level
- ACTH-independent Cushing's (adrenal adenoma): ACTH low (negative feedback). Does NOT suppress with high-dose dexamethasone (no pituitary to respond)
- ACTH-dependent Cushing's: ACTH elevated. Two causes: (1) Cushing's disease (pituitary adenoma) vs (2) Ectopic ACTH (SCLC)
- High-dose dexamethasone test: Cushing's DISEASE (pituitary) = cortisol SUPPRESSES (>50% reduction) — pituitary retains some feedback sensitivity. Ectopic ACTH (SCLC) = cortisol does NOT suppress — ectopic source has no feedback regulation
- New USMLE angle: If CRH is given and ACTH rises + cortisol rises → Cushing's disease (pituitary responds to CRH). If no response → ectopic ACTH source. MRI pituitary to confirm
Cushing Syndrome — Complete Diagnostic Algorithm
| Step | Test | Result | Interpretation |
|---|---|---|---|
| 1. Screen | 24-hr urine cortisol OR late-night salivary cortisol OR low-dose dex suppression test | Cortisol not suppressed (abnormal) | Cushing's syndrome confirmed — now find cause |
| 2. ACTH | Plasma ACTH level | ACTH low/undetectable | ACTH-independent → adrenal adenoma → CT adrenal |
| 2. ACTH | Plasma ACTH level | ACTH elevated | ACTH-dependent → differentiate pituitary vs ectopic |
| 3a. High-dose dex | 8mg dexamethasone overnight | Cortisol suppresses >50% | Cushing's DISEASE (pituitary adenoma) — retains feedback |
| 3a. High-dose dex | 8mg dexamethasone overnight | Cortisol does NOT suppress | Ectopic ACTH (SCLC most common) — no feedback |
| 3b. CRH stimulation | Give CRH → measure ACTH + cortisol | Rise in ACTH + cortisol | Pituitary adenoma responds to CRH |
| 4. Imaging | MRI pituitary (Cushing's disease) or CT chest/abdomen (ectopic) | — | Locate the source |
Clinical Features of Cushing Syndrome
Central obesity, moon facies, buffalo hump, purple striae (↑ cortisol → ↓ collagen → thin skin), proximal muscle weakness, HTN (cortisol acts like aldosterone → ↑ Na/H₂O reabsorption), hypokalemia + metabolic alkalosis, hyperglycemia (↑ gluconeogenesis), osteoporosis, impaired wound healing, immunosuppression.
Nelson Syndrome
After bilateral adrenalectomy for Cushing's disease: the pituitary adenoma (no longer suppressed by cortisol) grows aggressively → very high ACTH + MSH → hyperpigmentation + mass effect (headache, visual field defects). Prevent with radiation to pituitary after adrenalectomy.
RR 119EP577
Cushing Syndrome, Postoperative Adrenal Insufficiency
- Cortisol mimics aldosterone: Weight gain + HTN + hypokalemia + metabolic alkalosis + purple striae = Cushing's until proven otherwise
- Postoperative adrenal insufficiency: Patient on chronic steroids → surgical stress → relative adrenal insufficiency → hypotension not responding to fluids. Give IV hydrocortisone (stress dose steroids)
- Adrenal insufficiency (Addison's): Primary = adrenal gland destroyed (autoimmune most common in US; TB in developing world). Low cortisol + low aldosterone + high ACTH → hyperpigmentation (ACTH/MSH). Hyponatremia + hyperkalemia + hypotension
- Secondary adrenal insufficiency: Pituitary fails → low ACTH → low cortisol; aldosterone intact (RAAS independent of pituitary). NO hyperpigmentation. NO hyperkalemia
- Pheochromocytoma: Episodic HTN + headache + diaphoresis + palpitations (5 Ps). ↑ urine metanephrines/catecholamines. Treat: alpha-blockade (phenoxybenzamine) BEFORE beta-blockade. Surgery curative
Primary vs Secondary Adrenal Insufficiency
| Primary (Addison's) | Secondary (Pituitary) | |
|---|---|---|
| ACTH | ↑↑ (no feedback) | ↓ (pituitary fails) |
| Cortisol | ↓ | ↓ |
| Aldosterone | ↓ (zona glomerulosa destroyed) | Normal (RAAS intact) |
| Na/K | ↓Na, ↑K (aldosterone gone) | ↓Na only (mild — ADH effect) |
| Hyperpigmentation | Yes (↑ ACTH → ↑ MSH) | No (ACTH low) |
| Most common cause | Autoimmune (US); TB (worldwide) | Exogenous steroid use → HPA suppression |
| Cosyntropin stim test | Cortisol does NOT rise (adrenal destroyed) | Delayed response (atrophied adrenal slowly recovers) |
Alpha Before Beta — Pheo Surgery Rule
In pheochromocytoma: ALWAYS give alpha-blockade (phenoxybenzamine) for 1-2 weeks BEFORE giving beta-blocker or before surgery. If you give β-blocker first → unopposed α stimulation → severe hypertensive crisis. Only then add β-blocker (propranolol) to control reflex tachycardia from the alpha blockade.
EP514
A Framework for Understanding Endocrine Testing
- The two rules of endocrine testing: (1) Hormone deficiency → confirmatory test is a STIMULATION test; (2) Hormone excess → confirmatory test is a SUPPRESSION test
- Deficiency → stimulate the gland: If the gland can respond, deficiency is upstream (pituitary/hypothalamus). If no response, the gland itself is destroyed (primary failure)
- Excess → suppress the axis: If normal tissue, it will suppress. If autonomous (adenoma/ectopic), it will NOT suppress
- Hashimoto's example: Screen with TSH (↑) → confirm with anti-TPO antibodies → this is primary hypothyroidism (thyroid gland failure)
- Acromegaly example: Screen with IGF-1 (↑) → confirm with oral glucose tolerance test → normal: GH suppresses; acromegaly: GH does NOT suppress. Autonomous GH secretion from pituitary
Stimulation vs Suppression — Applied to Common Conditions
| Condition | Type | Confirmatory Test | Positive Result |
|---|---|---|---|
| Primary hypothyroidism | Deficiency | TSH (screen) + anti-TPO | TSH ↑↑, T4 ↓, positive Ab |
| Secondary hypothyroidism | Deficiency | TRH stimulation test | TSH fails to rise → pituitary failure |
| Adrenal insufficiency | Deficiency | Cosyntropin (ACTH) stimulation test | Cortisol fails to rise → adrenal failure |
| Central adrenal insufficiency | Deficiency | Insulin tolerance test OR metyrapone test | ACTH fails to rise appropriately |
| Cushing syndrome | Excess | Low-dose dex suppression OR 24-hr urine cortisol | Cortisol not suppressed |
| Acromegaly (GH excess) | Excess | Oral glucose tolerance test | GH not suppressed to <1 ng/mL after glucose load |
| Hyperaldosteronism (Conn's) | Excess | PAC:PRA ratio >30 + salt loading test | Aldosterone not suppressed with salt load |
| Pheochromocytoma | Excess | 24-hr urine metanephrines/catecholamines | Elevated >2× normal |
Acromegaly — What the USMLE Tests
Screen: IGF-1 (most sensitive). Confirm: oral glucose tolerance test (GH should suppress to <1 ng/mL — if not, autonomous). Cause: pituitary somatotroph adenoma. Features: large hands/feet/jaw (prognathism), increased ring/shoe size, deep voice, carpal tunnel syndrome, glucose intolerance, colonic polyps (↑ colon cancer risk), hypertension, sleep apnea. Treatment: surgery (transsphenoidal), then octreotide if residual.
EP602
Endocrine Thinking — Stimulation and Suppression Tests
- Hypothalamic-pituitary-target organ axis: Hypothalamus releases → anterior pituitary responds → target organ secretes → product feeds back to suppress hypothalamus AND pituitary
- Graves thyroglobulin insight: TSH receptor stimulating antibodies (TRAb) continuously stimulate thyroid → ↑ thyroglobulin. Thyroglobulin is elevated in all conditions where thyroid is actively secreting — not in exogenous thyroid hormone ingestion
- TSH-secreting pituitary adenoma: Rare cause of hyperthyroidism where TSH is NOT suppressed (paradoxically elevated). If you see ↑ TSH + ↑ T4 → think thyrotropinoma (not primary hypo/hyperthyroidism)
- Water deprivation test (DI): Deprive water → urine osmolality should rise. If it doesn't (stays dilute) → give desmopressin → if urine concentrates = central DI (ADH deficiency); if stays dilute = nephrogenic DI (receptor resistance)
- SIADH suppression: Confirm with water loading test — give oral water load → normal kidneys dilute urine to excrete it; SIADH continues to retain water (urine osmolality remains inappropriately high)
Central DI vs Nephrogenic DI vs SIADH
| Central DI | Nephrogenic DI | SIADH | |
|---|---|---|---|
| Problem | No ADH production (pituitary) | Kidneys don't respond to ADH | Excess ADH (or ADH-like) |
| Serum Na | ↑ (hypernatremia) | ↑ (hypernatremia) | ↓ (hyponatremia) |
| Urine osmolality | Very ↓ (<300) dilute | Very ↓ dilute | ↑ (concentrated, >100) |
| Desmopressin response | Urine concentrates ✓ | No response ✗ | N/A |
| Causes | Pituitary surgery, trauma, craniopharyngioma | Lithium, demeclocycline, hypercalcemia, hypokalemia | SCLC, CNS disorders, pulmonary disease, drugs (SSRIs) |
| Treatment | Desmopressin (DDAVP) | Thiazides + low-Na diet; treat cause | Water restriction; tolvaptan if severe |
Diabetes & Glucose
Three dedicated episodes plus a Rapid Review GLP-1 segment cover diabetes from molecular insulin biology through clinical management. EP482 (insulin pharmacology) and EP395 (management algorithm) together give the exam-ready framework for all DM questions; EP303 adds the critical drug interaction pitfalls and complication management that Step 2/3 tests most aggressively.
EP482
The Floridly HY Insulin Podcast
- Insulin biology: Peptide hormone from beta cells (central islets); alpha cells (peripheral islets) make glucagon. Insulin = proinsulin → cleaved to insulin + C-peptide. C-peptide elevated in endogenous hyperinsulinism; LOW in exogenous insulin injection
- DKA hallmarks: Type 1 DM (no insulin → lipolysis → ketoacid production). Glucose ↑, bicarb ↓, pH ↓, anion gap ↑. Kussmaul respirations (deep, blowing off CO2). AMS. Treat: IV fluids → insulin drip → K+ replacement (always check K+ first — add K+ if <3.5, hold insulin if K+ <3.3)
- HHS (hyperosmolar hyperglycemic state): Type 2 DM. Extreme hyperglycemia (>600) + hyperosmolarity + NO significant ketosis. Profound dehydration. Treat: massive IV fluids, then insulin
- DKA vs HHS distinguishing: DKA = ketones, acidosis, typically T1DM. HHS = no ketones, no acidosis, extreme hyperglycemia, typically T2DM elderly with precipitating illness
- Insulin types by duration: Rapid (lispro, aspart, glulisine — meal coverage); Short (regular — IV use, sliding scale); Intermediate (NPH); Long (glargine, detemir — basal, peakless)
DKA Management — Step by Step
| Step | Action | Key Detail |
|---|---|---|
| 1. Fluids | Normal saline 1L/hr bolus, then 200–500 mL/hr | Corrects hypovolemia before insulin (insulin further drops glucose AND K+) |
| 2. Check K+ | Potassium level | K+ may appear normal/high (acidosis drives K+ out of cells) — will drop dramatically with insulin |
| 3. If K+ <3.3 | HOLD insulin, give K+ replacement first | Insulin will crash K+ → fatal arrhythmia |
| 4. Insulin drip | Regular insulin IV 0.1 units/kg/hr | When glucose <200 → add dextrose to fluids to prevent hypoglycemia while anion gap closes |
| 5. Goal | Anion gap closure, NOT just glucose normalization | Keep running insulin until AG normal (<12). Can switch to SubQ insulin when eating and AG closed |
C-Peptide Distinguishes Endogenous vs Exogenous
High glucose + high insulin + high C-peptide → endogenous hyperinsulinism (insulinoma, sulfonylurea abuse — sulfonylureas stimulate beta cells to make insulin + C-peptide).
High glucose + high insulin + LOW C-peptide → exogenous insulin injection (factitious hypoglycemia — person is secretly injecting insulin, which is processed without C-peptide).
Sulfonylurea screen: urine drug screen to differentiate from insulinoma.
Insulin Types
| Type | Onset | Peak | Duration | Use |
|---|---|---|---|---|
| Rapid (lispro, aspart, glulisine) | 5-15 min | 1 hr | 3-4 hr | Meal coverage — give right before eating |
| Short (regular) | 30-60 min | 2-4 hr | 6-8 hr | IV drip in DKA; sliding scale |
| Intermediate (NPH) | 1-3 hr | 4-10 hr | 12-18 hr | Twice daily; hypoglycemia at peak |
| Long (glargine, detemir) | 1-2 hr | No peak | 20-24 hr | Basal once daily; no mixing with other insulins |
EP395
The Clutch Diabetes Management Podcast
- T2DM management ladder: (1) Lifestyle → (2) Metformin 1st line → (3) Add second agent based on comorbidities → (4) If A1C still uncontrolled, add insulin
- Metformin mechanism: Activates AMPK → ↓ hepatic gluconeogenesis; does NOT cause hypoglycemia (does not stimulate insulin secretion); lactic acidosis risk (hold for contrast, surgery, heart failure, renal failure)
- Add-on by comorbidity: CVD or high CV risk → GLP-1 agonist or SGLT2 inhibitor (empagliflozin/canagliflozin reduce CV events and slow CKD progression). CKD → SGLT2 inhibitor or GLP-1. Heart failure → SGLT2 (reduces hospitalizations)
- SGLT2 inhibitors side effects: Euglycemic DKA (rare but tested), UTI/yeast infections, Fournier's gangrene (necrotizing fasciitis of perineum), AKI (dehydration). Stop before surgery
- Insulin initiation in T2DM: Start at 0.5 units/kg/day. Split 50% basal (long-acting) + 50% divided over 3 meals (rapid-acting). Titrate fasting glucose to 80-130
Antidiabetic Drug Classes — USMLE Summary
| Drug | Mechanism | Hypoglycemia? | Key Side Effects / CI |
|---|---|---|---|
| Metformin | ↓ Hepatic gluconeogenesis (AMPK) | No | Lactic acidosis (CI: CKD, contrast, HF); GI upset; hold before surgery |
| Sulfonylureas (glipizide, glyburide) | Close K-ATP channels in beta cells → insulin release | Yes ↑↑ | Weight gain; hypoglycemia (especially glyburide in elderly) |
| SGLT2 inhibitors (-flozin) | Block glucose reabsorption in proximal tubule → glucosuria | No (except with insulin) | UTI/yeast, Fournier's gangrene, euglycemic DKA, AKI; CV/renal protection |
| GLP-1 agonists (liraglutide, semaglutide) | Stimulate glucose-dependent insulin, suppress glucagon, delay gastric emptying | No (alone) | N/V, pancreatitis (rare); CI in MEN2/medullary thyroid cancer; weight loss |
| DPP-4 inhibitors (-gliptin) | Increase endogenous GLP-1 by blocking its breakdown | No | Nasopharyngitis; heart failure (saxagliptin) |
| Thiazolidinediones (TZDs — pioglitazone) | PPAR-γ agonist → ↑ insulin sensitivity in fat/muscle | No | Weight gain, fluid retention, CHF, bladder cancer (pioglitazone), fractures |
| Insulin | Binds insulin receptor → glucose uptake | Yes | Hypoglycemia, weight gain, lipodystrophy at injection sites |
GLP-1 Agonists — Contraindication
GLP-1 agonists (liraglutide, semaglutide, exenatide) are contraindicated in patients with a personal or family history of medullary thyroid cancer or MEN2. Animal studies showed C-cell hyperplasia. This is a Class D contraindication on the USMLE — do not prescribe to anyone with MEN2A/2B or medullary thyroid cancer history.
EP303
Diabetes Part 3 - DKA/HHS, Diagnostic Criteria & Gestational Diabetes
- Beta-blockers in diabetics: Blunt adrenergic (neuroglycopenic) symptoms of hypoglycemia (sweating, tachycardia) — patient cannot sense hypoglycemia coming. Not absolutely contraindicated, but use with caution. Cardioselective (metoprolol, atenolol) preferred
- Counter-regulatory hormones: Glucagon (most important), epinephrine, cortisol, growth hormone — all raise blood glucose. Beta-blockers blunt epinephrine response but not glucagon, so glucagon can still rescue from severe hypoglycemia
- Diabetic complications: Microangiopathy → nephropathy (albumin in urine → ACE inhibitor/ARB), retinopathy (laser photocoagulation for proliferative), neuropathy (gabapentin/duloxetine). Macroangiopathy → CAD, stroke, PVD
- Chronic pancreatitis + diabetes: Pancreas destroyed → no endogenous insulin → insulin is ONLY option (oral agents won't work — no beta cells to stimulate)
- Thiamine before glucose in AMS: In any malnourished/alcoholic patient with altered mental status, give IV thiamine BEFORE IV dextrose — glucose without thiamine → Wernicke's encephalopathy (thiamine-dependent glucose metabolism)
Diabetic Complications — Screening and Management
| Complication | Screening | First Sign | Management |
|---|---|---|---|
| Nephropathy | Annual urine albumin-to-creatinine ratio | Microalbuminuria (30-300 mg/day) | ACE inhibitor or ARB (even if normotensive); SGLT2 for renal protection |
| Retinopathy | Annual dilated eye exam | Microaneurysms → dot/blot hemorrhages → cotton wool spots → neovascularization | Non-proliferative: control glycemia/BP; Proliferative: laser photocoagulation |
| Neuropathy | Monofilament exam (10g Semmes-Weinstein) | Stocking-glove numbness/tingling; loss of vibration/proprioception distally | Gabapentin, pregabalin, duloxetine (SNRIs), TCAs; foot care |
| Autonomic neuropathy | Clinical (orthostatic hypotension, gastroparesis) | Gastroparesis (early satiety, nausea, erratic glucose); orthostatic symptoms | Metoclopramide for gastroparesis; compression stockings; midodrine |
| Macrovascular (CVD) | Lipid panel, BP monitoring, ECG | Atypical MI presentation (painless MI more common in diabetics — autonomic neuropathy) | Statin + aspirin + ACE inhibitor; SGLT2/GLP-1 for CV risk reduction |
EP466
GLP-1 Agonists - Mechanism, Benefits & USMLE Angles
- GLP-1 mechanism: Incretin hormone — stimulates glucose-dependent insulin secretion (only when glucose is elevated → NO hypoglycemia alone), suppresses glucagon, delays gastric emptying (→ weight loss, early satiety)
- Drugs: Exenatide (twice daily), liraglutide (once daily), semaglutide (once weekly, also oral form), dulaglutide. Add-on to metformin when A1C uncontrolled + patient needs weight loss + CVD risk
- CVD benefit: Liraglutide and semaglutide reduce MACE (major adverse cardiac events) — FDA-approved for CV risk reduction in T2DM with established CVD
- Side effects: Nausea/vomiting (most common, dose-dependent), pancreatitis (monitor amylase/lipase if abdominal pain). Injectable (except oral semaglutide)
- Best candidate: T2DM + obesity (BMI >30) + inadequate control on metformin ± prior CVD or CKD → GLP-1 agonist preferred over sulfonylurea
GLP-1 vs DPP-4 — The Incretin Drug Comparison
| GLP-1 Agonists | DPP-4 Inhibitors | |
|---|---|---|
| Mechanism | Exogenous GLP-1 analog (supraphysiologic levels) | Block DPP-4 enzyme → preserve endogenous GLP-1 |
| A1C reduction | 1-2% (greater) | 0.5-1% (modest) |
| Weight | Weight loss (↓ 3-5 kg) | Weight neutral |
| CV benefit | Yes (liraglutide, semaglutide) | Saxagliptin may ↑ HF hospitalizations |
| Side effects | N/V, pancreatitis, CI in MEN2/medullary Ca | Nasopharyngitis, upper URI, arthralgia |
| Route | SubQ injection (except oral semaglutide) | Oral tablet |
| Hypoglycemia | No (glucose-dependent) | No |
Calcium, Bone & Parathyroid
EP348 covers hypercalcemia comprehensively — the differential, the "stones bones groans" mnemonic unpacked, and the mechanism behind every cause. Hypercalcemia questions are almost always about identifying the correct cause from the vignette context, not just recognizing high calcium.
EP348
The Clutch Hypercalcemia Podcast
- Symptoms (Stones Bones Groans Psychic Overtones): Nephrolithiasis, bone pain/osteitis fibrosa cystica, constipation/N/V/pancreatitis, depression/confusion/AMS. Symptoms worse when Ca >12.5
- Most common causes: Outpatient = primary hyperparathyroidism (asymptomatic, hypophosphatemia, ↑ PTH, ↑ urinary cAMP). Inpatient/malignancy = PTHrP (squamous cell lung cancer, breast, renal, multiple myeloma — osteolytic)
- PTH vs PTHrP: Primary hyperparathyroidism: ↑PTH, ↑urine Ca, ↓phosphorus. Malignancy (PTHrP): ↓PTH (suppressed by hypercalcemia), ↑PTHrP — PTHrP does NOT stimulate 1-α hydroxylase → 1,25-OH vit D is LOW
- Sarcoidosis/granulomatous: Macrophages in granuloma produce 1-α hydroxylase → ↑ 1,25-OH vit D → ↑ GI calcium absorption. ↓ PTH (suppressed). Treat with steroids (suppress macrophage activity)
- Acute hypercalcemia management: IV normal saline (hydration) → furosemide (promotes Ca excretion) → bisphosphonates (pamidronate/zoledronic acid for malignancy) → calcitonin (rapid onset, tachyphylaxis)
Hypercalcemia Differential — Complete Table
| Cause | PTH | PTHrP | Vit D (1,25-OH) | Phosphorus | Classic Context |
|---|---|---|---|---|---|
| Primary hyperparathyroidism | ↑↑ | Normal | ↑ (PTH stimulates 1α-hydroxylase) | ↓ | Asymptomatic, outpatient, solitary adenoma |
| Malignancy (PTHrP) | ↓ (suppressed) | ↑↑ | Normal or ↓ | ↓ | Squamous cell lung Ca, RCC, breast Ca; osteolytic mets |
| Multiple myeloma | ↓ | Normal | Normal | Normal | RANK-L mediated osteoclast activation; lytic lesions on bone survey |
| Sarcoidosis/granulomas | ↓ | Normal | ↑↑ (macrophage 1α-hydroxylase) | Normal/↑ | Bilateral hilar adenopathy, non-caseating granulomas; treat with steroids |
| Vitamin D toxicity | ↓ | Normal | ↑↑ | ↑ | Excess supplementation; granulomatous disease |
| Thiazide diuretics | Normal/↑ | Normal | Normal | Normal | Thiazides ↓ urinary Ca excretion; mild hypercalcemia |
| Familial hypocalciuric hypercalcemia | Normal/↑ | Normal | Normal | Normal | Benign; low 24-hr urine Ca; Ca:Cr ratio <0.01; do nothing |
Acute Hypercalcemia Management Sequence
1. IV Normal Saline: Aggressive hydration — dilutes calcium + promotes calciuresis (Ca excretion follows Na).
2. Furosemide: Only AFTER adequate hydration (prevents volume overload + promotes Ca excretion). Never give before fluids.
3. Bisphosphonates (zoledronic acid): Inhibit osteoclasts — takes 2-4 days to work; best for malignancy-related.
4. Calcitonin: Fastest onset (hours); short-lived (tachyphylaxis in 48 hrs); use as bridge while waiting for bisphosphonates.
5. Steroids (hydrocortisone): For granulomatous disease (sarcoidosis) and lymphoma (inhibits vitamin D production).
Also Covered In Other Episodes
Divine’s rapid-review episodes mix several systems into one recording. These episodes are filed under another system but contain a substantial Endocrinology segment. The title names the whole episode; the bullets are the Endocrinology portion only.
RR 115 EP536EP536
Rapid Review 115 - Presbycusis & Ototoxic Drugs, Nicotine Withdrawal, Migraine, MAOI Crisis
Cross-listed. This episode is filed under MSK & Rheumatology. Below is only its Endocrinology content.
- Hashimoto hypothyroidism presenting with fatigue, bradycardia and infertility
- Bradycardia mechanism: T3 is needed to insert beta-1 receptors on myocardial cells
- Hypothyroid infertility mechanism: high TRH drives hyperprolactinemia, prolactin suppresses GnRH, producing hypogonadotropic hypogonadism
- Hereditary hemochromatosis (HFE mutation) with red skin, erectile dysfunction, hypopituitarism and diabetes; why hypopituitary hypocortisolism does NOT cause ACTH-driven hyperpigmentation
RR 105 EP488EP488
Rapid Review 105 - SCLC Paraneoplastics, ADH Physiology, Diabetes Insipidus, Lambert-Eaton
Cross-listed. This episode is filed under Neurology. Below is only its Endocrinology content.
- Ectopic ACTH from small cell lung cancer: POMC-derived MSH causing skin hyperpigmentation
- Cortisol acting like aldosterone in excess, producing hypokalemia and metabolic alkalosis
- High-dose dexamethasone non-suppression as the classic ectopic ACTH finding
- ADH/vasopressin physiology and the central versus nephrogenic diabetes insipidus workup
RR 122 EP601EP601
Rapid Review 122 - Iatrogenic Cushing Syndrome, SIADH, DiGeorge & Hyperparathyroidism
Cross-listed. This episode is filed under Gastrointestinal. Below is only its Endocrinology content.
- Iatrogenic Cushing syndrome from prolonged corticosteroid therapy is the most common cause of cortisol excess; presents with weight gain and abdominal striae
- SIADH: low serum osmolality with high urine osmolality and hyponatremia causing altered mental status; explained mechanistically via ADH-driven free water reabsorption
- Drug and disease causes of SIADH: chlorpropamide (a sulfonylurea), SSRIs, carbamazepine, small cell lung cancer, plus brain and pulmonary pathology
- Primary hyperparathyroidism: high serum calcium, high urinary calcium, low phosphate; subperiosteal resorption along lateral middle phalanges on hand radiograph
- Parathyroid adenoma is the most common cause, hyperplasia second; MEN1 (menin) and MEN2A (RET) associations, MEN2B does not include it
- Familial hypocalciuric hypercalcemia: calcium-sensing receptor mutation gives high PTH and high calcium but LOW urinary calcium; no treatment needed
EP298
Esophageal Rings & Webs, Zenker Diverticulum, Peptic Ulcer Disease, Zollinger-Ellison
Cross-listed. This episode is filed under Gastrointestinal. Below is only its Endocrinology content.
- MEN1 presenting with chronic diarrhea (Zollinger-Ellison), polyuria/polydipsia, and enlarging hands, feet and facial features
- Hypercalcemia causes nephrogenic diabetes insipidus by impairing the principal cell response to ADH, explaining polyuria and polydipsia
- Acromegaly workup: screen with IGF-1 (not random growth hormone), confirm with failure of GH suppression after oral glucose, then brain MRI
- Acromegaly treatment: transsphenoidal resection; octreotide or pegvisomant (growth hormone receptor antagonist) if a poor surgical candidate
EP408
Rapid Review 81 - Postoperative Fever, Malignant Hyperthermia, Ludwig Angina, Dumping Syndrome
Cross-listed. This episode is filed under Gastrointestinal. Below is only its Endocrinology content.
- Chronic exogenous cortisol suppresses the hypothalamic-pituitary-adrenal axis (CRH to ACTH to cortisol and sex steroids)
- Aldosterone is not under ACTH control, so it remains normal in chronic steroid users
- Aldosterone rises only when volume depletion activates the renin-angiotensin-aldosterone system, provided the adrenal cortex is functional
- Cortisol raises white blood cell count by demarginating neutrophils
EP571
Quick and Dirty EM - Airway Management, Oxygen Delivery, Shock Types & Adrenal Crisis
Cross-listed. This episode is filed under Emergency Medicine. Below is only its Endocrinology content.
- Addison disease as a cause of shock, clustering with other autoimmune disease such as celiac disease
- Adrenal cortex (mesoderm) versus adrenal medulla (neural crest) and why autoimmune destruction spares the medulla
- Aldosterone and cortisol deficiency producing hyponatremia, hyperkalemia, normal anion gap metabolic acidosis and loss of catecholamine responsiveness
- Myxedema coma from untreated Hashimoto's with very low T3/T4 and very high TSH, hypotension from reduced beta-1 receptor insertion on cardiac myocytes, treated with IV levothyroxine
- Adrenal crisis in patients on chronic steroids with a suppressed HPA axis, rescued with stress-dose steroids plus fludrocortisone